Format

Send to

Choose Destination
Curr Opin Pharmacol. 2018 Jun;40:87-94. doi: 10.1016/j.coph.2018.03.010. Epub 2018 Apr 4.

Targeting therapeutics to bone by conjugation with bisphosphonates.

Author information

1
Department of Chemistry, Simon Fraser University, Burnaby, BC, Canada. Electronic address: robert_young@sfu.ca.
2
Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, and University of Toronto, Toronto, ON, Canada.

Abstract

Bisphosphonates target and bind avidly to the mineral (hydroxyapatite) found in bone. This targeting ability has been exploited to design and prepare bisphosphonate conjugate prodrugs to deliver a wide variety of drug molecules selectively to bones. It is important that conjugates be stable in the blood stream and that conjugate that is not taken up by bone is eliminated rapidly. The prodrugs should release active drug at a rate appropriate so as to provide efficacy. Radiolabelling is the best method to quantify and evaluate pharmacokinetics, tissue distribution, bone uptake and release of the active drug(s). Recent reports have described bisphosphonate conjugates derived from the antiresorptive drug, alendronic acid and anabolic prostanoid drugs that effectively deliver prostaglandins and prostaglandin EP4 receptor agonists to bone and show enhanced anabolic efficacy and tolerability compared to the drugs alone. These conjugate drugs can be dosed infrequently (weekly or bimonthly) whereas the free drugs must be dosed daily.

PMID:
29626715
DOI:
10.1016/j.coph.2018.03.010
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center